In Defense of the Weeds
Milk thistle is scientifically proven to help with liver-related ailments including fatty liver, cirrhosis, bile duct disease, and toxemia from acute poisoning (such as from eating poisonous mushrooms) and chronic poisoning (such as from alcohol abuse ...
The Mountain -Ear - Mon, 21 Jul 2014 07:26

Intercept Pharmaceuticals Names Lazar Partners Agency of Record
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. ... Lazar Partners will ...
Marketwired (press release) - Thu, 10 Jul 2014 07:03

Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs
Ursodiol is the only drug approved to treat PBC, a disease characterized by bile ducts in the liver being slowly destroyed, which can lead to irreversible scarring of the liver. Note, this is not NASH, but it is promising for OCA in general as ...
MarketWatch - Thu, 26 Jun 2014 06:43

Doctors told me it was terminal - they were wrong
At that visit I was diagnosed with a terminal liver disease: primary biliary cirrhosis. She printed me off a Wikipedia explanation and asked me how fast I could book in with a private gastroenterologist. She failed to tell me the disease was terminal ... - Mon, 07 Jul 2014 16:47

Intercept Pharmaceuticals' Drop Proves How Impatient Investors Are
Right now, Intercept Pharmaceuticals has run phase 3 trials on obeticholic acid's use in treating primary biliary liver cirrhosis, and it is also running a phase 2 trial for the treatment's use for nonalcoholic steatohepatitis or NASH. So far ...
Motley Fool - Thu, 26 Jun 2014 16:06

Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following ...
Benzinga - Thu, 26 Jun 2014 09:18

5 of Last Week's Biggest Losers
Intercept is an upstart biotech trying to get its obeticholic acid to market for the treatment of primary biliary liver cirrhosis and nonalcoholic steatohepatitis, or NASH. The cirrhosis study is in the final stage of clinical trials, but the NASH ...
Motley Fool - Sun, 29 Jun 2014 10:26

Intercept Pharmaceutical Stock Gains Over 200% This Year
Intercept Pharmaceuticals' lead experimental drug targets a range of liver diseases including primary biliary cirrhosis, portal hypertension, and NASH. So far, there are no specific treatment plans available for those with the disease. There are also ...
Bidness Etc - Tue, 08 Jul 2014 02:53

Actavis, Forest To Sell or Relinquish Generics Rights
According to the FTC complaint, Actavis's ACT +1.51% acquisition, as originally proposed, would reduce competition for three current generic product used to treat hypertension and chronic stable angina, primary biliary cirrhosis of the liver and ...
Wall Street Journal - Mon, 30 Jun 2014 14:33

1  2  3  4  5  6  7  8    ->

Last update: April 2009